Elevara Medicines Doses First Patient in Phase 2b START-SYNERGY Trial of ELV001 in Rheumatoid Arthritis Patients with Incomplete Response to TNFiLondon, UK – 16 March 2026 – Elevara Medicines (“Elevara”), a clinical-stage biotech developing therapies for rheumatoid arthritis (RA) and chronic inflammatory diseases, today announced dosing of the first patient in the Phase 2b START-SYNERGY clinical trial evaluating ELV001, a novel oral CDK4/6 inhibitor, in patients with rheumatoid arthritis (RA) who have an incomplete response to methotrexate (MTX) and tumour necrosis factor (TNF) inhibitors.
